# Patient Experience with Medical Cannabis: Development of the Utah Medical Cannabis Prospective Cohort Evaluation

A. Taylor Kelley, MD, MPH, MSc<sup>1-4</sup> Clinton J. Hardy, PhD, LCSW,<sup>2</sup> Michael A. Incze, MD, MSEd,<sup>1,2</sup> Adam J. Gordon, MD, MPH,<sup>2-4</sup> Kathryn Szczotka, MPH,<sup>2</sup> Kristi Carlston,<sup>2</sup> Rajiv Radhakrishnan, MBBS, MD, MHS,<sup>5-6</sup> Samuel T. Wilkinson, MD,<sup>5</sup> Gerald Cochran, PhD<sup>2,4</sup>

<sup>1</sup> Department of Internal Medicine, Division of General Internal Medicine; <sup>2</sup> Program of Addiction Research, Clinical Care, Knowledge, and Advocacy (PARCKA), Department of Internal Medicine, University of Utah School of Medicine; <sup>3</sup> Vulnerable Veteran Innovative Patient-Aligned Care Team, VA Salt Lake City Health Care System; <sup>4</sup> Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center, VA Salt Lake City Health Care System; 5 Department of Psychiatry, Yale School of Medicine; 6 Department of Radiology and Biomedical Engineering, Yale School of Medicine

# BACKGROUND

- Medical Cannabis (MC) is now legal in 41 states and the District of Columbia
- † indications for MC use
- Patient experience with MC programs not established




- Legalized 2018 for medical use only
- Requires MC card from state-certified clinician
- ~69,000 patients have a current MC card
- 14 authorized dispensaries
- Minimal feedback on user experience to date

## **OBJECTIVE**

 Partner with state MC program (Utah) to develop an evaluation responsive to program needs


# **METHODS**



Chronic Cancer-related

Symptoms


# RESULTS



# Stage 1 Evaluation Advisory Board









# Stage 3

Identify & address barriers to long-term prospective cohort evaluation

# **Board Composition (N=9)**

#### Participants (*n*=3) Patients with a medical cannabis card Leaders (*n*=3) **UMCS** officials & administrators Providers (*n*=3) Licensed prescribers, dispensary pharmacists

- Board Member Criteria: ✓ ≥18 years old
- ✓ ≥1 year as participant/leader/provider ✓ Live in Utah ✓ Commitment to attend Board meetings
- Provide operational, healthcare, & policy recommendations for future evaluation needs **Board Meetings** (virtual, 1 hour each, first monthly, then quarterly)
- Key Informant Interviews Year 1 Year 2

**Board Objectives** 

for all aspects of study

execution & completion

• Review & provide feedback on overall approach

Ensure decisions are informed & well-grounded

Identify resource needs to ensure successful

Guide reporting and dissemination of findings


• Review & provide feedback on assessments to

Inform approach to identify & engage participants

General

O2 & O3

be administered



Cannabis as Medicine (CAMS)	Patient Global Impression of Change (PGIC)	Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)	Satisfaction related to program operation
Patient-Reported Outcomes Measured Information System (PROMIS) Sleep Disturbance	Abbreviated World Health Organization Quality of Life Questionnaire (WHOQOL-BREF)	World Health Organization Disability Assessment Schedule (WHODAS 2.0)	Daily Sessions, Frequency, Age of Onset, & Quantity of Cannabis Use Inventory (DFAQ-CU)
Brief Pain Inventory (BPI)	Treatment Services Review-6 (TSR-6)	Short Form-36 (SF-36)	Patient Health Questionnaire (PHQ)
Medical Assessment of Cannabis Efficacy & Side Effects Scale (MACESS)	Graded Chronic Pain Scale-Revised (GCPS- R)	Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST)	Patient Satisfaction: Client Satisfaction Questionnaire-8 (CSQ-8)

- GOAL: Match MC data with patient health records
- GOAL: Assess long-term effects GOAL: Develop evidence base for specific indications



### RESULTS SUMMARY

#### Evaluation priorities:

- Enrollee experience
- Access to MC
- Therapeutic effects, especially for patients with PTSD, chronic pain, and cancer-related symptoms
- Feedback on how to improve MC program

# CONCLUSIONS

In a three-stage process over a two-year period, we will conduct a stakeholder-informed evaluation of patient experience and patientreported outcomes in a state MC program.

## **IMPLICATIONS**

Lays groundwork to evaluate longterm effects of MC and MC program, including patient-level outcomes

## FUNDING INFO & CONTACT

Utah Department of Health and Human Services (2022-2024): Utah Medical Cannabis: A Prospective Cohort Evaluation

Email: Alan.Kelley@hsc.utah.edu

Twitter: @ATaylorKelley





